STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] ANI Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Form 144 notice for ANI Pharmaceuticals, Inc. (ANIP) reports a proposed sale of 7,292 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $692,270.40 and stated approximate sale date of 09/03/2025. The filer identifies prior restricted stock acquisitions of 3,000 shares on 04/27/2023 and 4,292 shares on 03/23/2022, both received from the issuer, and discloses a sale during the past three months of 5,421 shares for $486,406.81 on 08/20/2025. The form includes the standard representation that the seller is not aware of any undisclosed material adverse information.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Insider sale disclosed; transaction size is small relative to total shares outstanding and appears routine.

The filing notifies the market of a planned sale of 7,292 common shares through Morgan Stanley Smith Barney with an indicated value of $692,270.40 and references recent restricted stock grants and a recent sale of 5,421 shares generating $486,406.81. With 21,688,772 shares outstanding, the planned sale represents roughly 0.03% of outstanding shares, suggesting limited immediate dilution or market impact. The disclosure is consistent with Rule 144 mechanics for restricted securities and includes the standard attestation about undisclosed material information.

TL;DR: Document fulfills disclosure obligations under Rule 144; provides dates and amounts for grants and recent sales.

The filer documents acquisition dates for restricted stock awards and lists a broker and planned sale date, meeting procedural requirements for public notice of proposed insider sales. The filing contains the prescribed representation regarding material nonpublic information and highlights a recent sale within the last three months. There are no statements here about changes in management, related-party issues, or other governance events; thus the filing appears to be a routine transparency disclosure rather than a governance red flag.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What insider sale does ANIP's Form 144 disclose?

The form discloses a proposed sale of 7,292 shares of ANIP common stock through Morgan Stanley Smith Barney with an aggregate market value of $692,270.40 and an approximate sale date of 09/03/2025.

What recent sales by the filer are reported in the past three months for ANIP?

The filing reports a sale on 08/20/2025 of 5,421 shares of common stock for gross proceeds of $486,406.81.

How many ANIP shares outstanding are shown on the Form 144?

The form indicates 21,688,772 shares of common stock outstanding.

When were the restricted stock grants acquired by the filer?

The filer received 4,292 shares as restricted stock on 03/23/2022 and 3,000 shares on 04/27/2023, both from the issuer.

Which broker is handling the proposed ANIP share sale?

The broker named on the form is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
Ani Pharmaceutic

NASDAQ:ANIP

ANIP Rankings

ANIP Latest News

ANIP Latest SEC Filings

ANIP Stock Data

1.96B
18.36M
10.42%
97.8%
9.42%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
BAUDETTE